A vitamin essential for human survival may have a dark side, new research reveals. Scientists have discovered that vitamin B2, commonly found in eggs, dairy, and leafy greens, can protect cancer cells from a natural form of cell death that the body normally uses to destroy tumors.
The finding emerged from work at the Rudolf Virchow Centre at Julius-Maximilians-Universität Würzburg, where researchers uncovered a troubling role for riboflavin, the chemical name for vitamin B2. The nutrient, which the body cannot manufacture and must obtain from food, appears to strengthen cancer cells' defenses against ferroptosis, a controlled cell death mechanism that normally keeps malignant growths in check.
"Vitamin B2 plays a crucial role in protecting cancer cells from ferroptosis," says PhD student Vera Skafar, part of a team led by Professor José Pedro Friedmann Angeli. The research was published in Nature Cell Biology.
Ferroptosis works differently from other forms of programmed cell death. It occurs when iron-driven damage overwhelms a cell's antioxidant defenses, triggering destruction without inflammatory fallout. Cancer cells typically survive by strengthening their protective systems against oxidative stress, and the new work shows vitamin B2 metabolism is central to that survival strategy.
From Lab Discovery to Potential Treatment
The research team focused on a protein called FSP1, which shields healthy cells from unwanted death and which vitamin B2 actively supports. Using genome editing and cancer cell models, scientists found that when vitamin B2 was limited, cancer cells became dramatically more vulnerable to ferroptosis.
This opened a therapeutic possibility: blocking vitamin B2 metabolism in tumors could trigger cancer cell death. The challenge is that no drug currently exists to do this. To test the concept, researchers turned to roseoflavin, a naturally occurring bacterial compound with a structure similar to vitamin B2.
The results were striking. In laboratory experiments, roseoflavin triggered ferroptosis in cancer cells at low concentrations, proving the underlying concept works. "Our experiments show the feasibility of this concept," Friedmann Angeli said.
The team is now developing more effective inhibitors of vitamin B2 metabolism and plans to test them in preclinical cancer models, with the goal of turning the discovery into a clinical therapy.
The implications extend well beyond cancer. Ferroptosis dysfunction contributes to neurodegenerative diseases, organ transplant rejection, and tissue damage from blocked blood flow. Understanding vitamin B2's role in ferroptosis could reshape how scientists approach these conditions and shed light on why the body sometimes kills too many cells or too few.
The work received funding from the German Research Foundation and an ERC Consolidator Grant worth nearly two million euros, awarded since May 2024.
Author Jessica Williams: "This is the kind of research that flips conventional wisdom on its head, but the real payoff comes only if scientists can crack the engineering problem and deliver a working drug before cancer cells adapt to it."
Comments